ClinicalTrials.gg
CompletedNCT01524497Updated Oct 16, 2014

A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression

A Phase 2/3 interventional study of Trazodone and Placebo in Depression, sponsored by Lee's Pharmaceutical Limited. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Lee's Pharmaceutical Limited · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Enrollment
44th of 284
382 · median 129
Started
2011
with 9 others
Phase 2/3
6 of 358
1 open now
Registered
22nd of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 44th largest by enrollment of the 284 interventional ones that give a count, is one of 10 that started in 2011, is one of 6 in phase 2/3, and was the 22nd registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,728 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,090 Depression studies recruiting now, 470 (43%) set no upper age limit and 520 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of trazodone hydrochloride prolonged-release tablets for treatment of depression in Chinese population.

03

Conditions studied

  • Depression

Keywords

  • losing interest and feelings of guilt
  • poor concentration
  • loss of appetite
  • suicide
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 65, males and females, outpatients or inpatients;
  2. Single episode or recurrent depression according to (Version 4) criteria;
  3. Scores > 18 on 17-item HAM-D at screening and baseline visits with a decrease not exceeding 20% between the two visits;
  4. Symptoms of depression for at least 1 month;
  5. Patients or their dependents/guardians providing signed forms.

Exclusion criteria

Exclusion Criteria:

  1. Serious suicide attempts (≥ 3 on item 3 'Suicide' of HAMD);
  2. Depressive episode, with psychotic symptoms;
  3. depression;
  4. Depressive episode secondary to other mental or physical disorders;
  5. Bipolar disorder;
  6. Significant reduction in body weight and malnutrition induced by major depression;
  7. Serious or unstable heart, hepatic, renal, endocrine and hematologic disease or malignant tumors;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
382 participants (actual)

Study arms

  • Active comparator
    Trazodone

    Drug: Trazodone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 75mg tablet/150 mg tablet

  • DrugPlacebo

    Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale-17 score

    17-item Hamilton Depression Rating scale were evaluated at the basemline and six weeks after treatment, the changes were recorded and used as primary outcome measurement.

    Time frame: six weeks

Secondary outcomes

  1. Changes in HAMA-14 score

    Change from baseline in HAMA-14 score at Visit 6/final visit

    Time frame: Six weeks

  2. CGI-Severity of illness and CGI-Global improvement

    CGI-Severity of illness and CGI-Global improvement at Visit 6/final visit

    Time frame: Six weeks

  3. Changes in evaluation of sleep quality and sexual dysfunction

    change from baseline in evaluation of sleep quality and sexual dysfunction at Visit 6/final visit

    Time frame: Six weeks

  4. Rate changes of responders/patients

    rate of responders, defined as patients with a 50% improvement from baseline in the HAMD score at Visit6/final visit;or rate of patients with remission, defined as patients with HAMD score ≤7 at Visit 6/final visit.

    Time frame: Six weeks

07

Study locations

1 site
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Feb 2, 2012
Start
Nov 2011
Primary completionActual
Aug 2013
CompletionActual
Nov 2013
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01524497
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Nov 2011
Primary completion
Aug 2013
Completion
Nov 2013
Last update
Oct 16, 2014

Study contacts

Benjamin LI, Ph.D.
study director · Lee's Pharmaceutical company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion